Clinical Trial Update: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating efficacy and safety of Ixoberogene Soroparvovec (Ixo-vec) for neovascular age-related macular degeneration is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• Ixo-vec (Ixoberogene soroparvovec)

Snippet

Sponsor: Adverum Biotechnologies, Inc. | Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | Status: RECRUITING